日付 | 受信時刻 | ニュースソース | 見出し | コード | 企業名 |
2025/02/21 | 21 : 00 | GlobeNewswire Inc. | Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results | AMEX:CATX | Perspective Therapeutics Inc |
2025/02/15 | 01 : 37 | Edgar (US Regulatory) | Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] | AMEX:CATX | Perspective Therapeutics Inc |
2025/02/15 | 00 : 26 | Edgar (US Regulatory) | Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] | AMEX:CATX | Perspective Therapeutics Inc |
2025/02/05 | 21 : 00 | GlobeNewswire Inc. | Perspective Therapeutics to Participate in Upcoming February Investor Conferences | AMEX:CATX | Perspective Therapeutics Inc |
2025/02/04 | 06 : 09 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:CATX | Perspective Therapeutics Inc |
2025/01/24 | 21 : 26 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:CATX | Perspective Therapeutics Inc |
2025/01/24 | 21 : 00 | GlobeNewswire Inc. | Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium | AMEX:CATX | Perspective Therapeutics Inc |
2025/01/22 | 21 : 00 | GlobeNewswire Inc. | Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025 | AMEX:CATX | Perspective Therapeutics Inc |
2025/01/13 | 22 : 36 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:CATX | Perspective Therapeutics Inc |
2025/01/13 | 22 : 00 | GlobeNewswire Inc. | Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference | AMEX:CATX | Perspective Therapeutics Inc |
2025/01/10 | 21 : 00 | GlobeNewswire Inc. | Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference | AMEX:CATX | Perspective Therapeutics Inc |
2025/01/08 | 06 : 50 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | AMEX:CATX | Perspective Therapeutics Inc |
2025/01/08 | 06 : 48 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | AMEX:CATX | Perspective Therapeutics Inc |
2025/01/06 | 22 : 05 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:CATX | Perspective Therapeutics Inc |
2025/01/06 | 22 : 00 | GlobeNewswire Inc. | Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer | AMEX:CATX | Perspective Therapeutics Inc |
2024/12/07 | 06 : 05 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | AMEX:CATX | Perspective Therapeutics Inc |
2024/12/05 | 07 : 20 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | AMEX:CATX | Perspective Therapeutics Inc |
2024/12/05 | 07 : 17 | Edgar (US Regulatory) | Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] | AMEX:CATX | Perspective Therapeutics Inc |
2024/12/05 | 07 : 15 | Edgar (US Regulatory) | Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] | AMEX:CATX | Perspective Therapeutics Inc |
2024/11/27 | 21 : 05 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | AMEX:CATX | Perspective Therapeutics Inc |
2024/11/27 | 21 : 00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | AMEX:CATX | Perspective Therapeutics Inc |
2024/11/27 | 21 : 00 | GlobeNewswire Inc. | Perspective Therapeutics to Participate in Upcoming Investor Conferences in December | AMEX:CATX | Perspective Therapeutics Inc |
2024/11/26 | 21 : 00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | AMEX:CATX | Perspective Therapeutics Inc |
2024/11/21 | 21 : 30 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:CATX | Perspective Therapeutics Inc |
2024/11/21 | 21 : 15 | GlobeNewswire Inc. | Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium | AMEX:CATX | Perspective Therapeutics Inc |
2024/11/16 | 06 : 08 | GlobeNewswire Inc. | Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024 | AMEX:CATX | Perspective Therapeutics Inc |
2024/11/15 | 21 : 30 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:CATX | Perspective Therapeutics Inc |
2024/11/15 | 08 : 14 | Edgar (US Regulatory) | Form SC 13G - Statement of Beneficial Ownership by Certain Investors | AMEX:CATX | Perspective Therapeutics Inc |
2024/11/15 | 06 : 05 | Edgar (US Regulatory) | Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] | AMEX:CATX | Perspective Therapeutics Inc |
2024/11/15 | 00 : 24 | Edgar (US Regulatory) | Form SC 13G - Statement of Beneficial Ownership by Certain Investors | AMEX:CATX | Perspective Therapeutics Inc |